Sritama Nath

2.5k total citations · 2 hit papers
22 papers, 2.0k citations indexed

About

Sritama Nath is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Sritama Nath has authored 22 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Oncology and 8 papers in Immunology. Recurrent topics in Sritama Nath's work include Glycosylation and Glycoproteins Research (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and CAR-T cell therapy research (6 papers). Sritama Nath is often cited by papers focused on Glycosylation and Glycoproteins Research (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and CAR-T cell therapy research (6 papers). Sritama Nath collaborates with scholars based in United States, Canada and Malaysia. Sritama Nath's co-authors include Pinku Mukherjee, Gayathri R. Devi, Lopamudra Das Roy, Mahnaz Sahraei, Dahlia M. Besmer, Sandra Gendler, Amritha Kidiyoor, Durai B. Subramani, Sun‐Il Hwang and K. Daneshvar and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Sritama Nath

22 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model

2016 688 citations Sritama Nath, Gayathri R. Devi Pharmacology & Therapeutics profile →
MUC1: a multifaceted oncoprotein with a key role in cancer progression

2014 652 citations Sritama Nath, Pinku Mukherjee Trends in Molecular Medicine profile →

Peers

Sritama Nath

ONCOL

IMMUN

Zhuo G. Chen United States

Seong‐Yun Jeong South Korea

Michele Zanoni Italy

Danilo Marimpietri Italy

Chiara Arienti Italy

Fabio Pastorino Italy

Fariba Némati France

Verónica Estrella United States

Carol Box United Kingdom

Letizia Porcelli Italy

Zhuo G. Chen United States

Sritama Nath

1.2k ×1.1

685 ×0.9

ONCOL

524 ×1.0

355 ×1.0

IMMUN

270 ×0.9

Citations per year, relative to Sritama Nath Sritama Nath (= 1×) peers Zhuo G. Chen

Countries citing papers authored by Sritama Nath

Since Specialization

Citations

This map shows the geographic impact of Sritama Nath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sritama Nath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sritama Nath more than expected).

Fields of papers citing papers by Sritama Nath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sritama Nath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sritama Nath. The network helps show where Sritama Nath may publish in the future.

Co-authorship network of co-authors of Sritama Nath

This figure shows the co-authorship network connecting the top 25 collaborators of Sritama Nath. A scholar is included among the top collaborators of Sritama Nath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sritama Nath. Sritama Nath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DiPersio, John F., Brenda Cooper, Hyung C. Suh, et al.. (2024). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).. Transplantation and Cellular Therapy. 30(2). S237–S238. 4 indexed citations

Shah, Nirali N., Jacques Azzi, Matthew Cooper, et al.. (2024). Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(2). S225–S226. 1 indexed citations

Koehne, Guenther, Benjamin Tomlinson, Hyung C. Suh, et al.. (2023). P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere. 7(S3). e24418bc–e24418bc. 3 indexed citations

DiPersio, John F., Matthew Cooper, Hyung C. Suh, et al.. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood. 142(Supplement 1). 483–483. 7 indexed citations

Shah, Nirali N., Jacques Azzi, Matthew Cooper, et al.. (2023). Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 142(Supplement 1). 4862–4862. 6 indexed citations

Bose, Mukulika, Priyanka Grover, Ru Zhou, et al.. (2022). Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. Frontiers in Cell and Developmental Biology. 10. 821875–821875. 17 indexed citations

Cooper, Brenda, Hyung C. Suh, Divya Koura, et al.. (2022). Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse. Blood. 140(Supplement 1). 12973–12975. 1 indexed citations

Sahraei, Mahnaz, Mukulika Bose, Joyce Sanders, et al.. (2021). Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models. International Journal of Molecular Sciences. 22(11). 5587–5587. 13 indexed citations

Curry, Jennifer M., Dahlia M. Besmer, Nury Steuerwald, et al.. (2019). Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice. PLoS ONE. 14(11). e0224309–e0224309. 19 indexed citations

10.

Grover, Priyanka, Sritama Nath, Monica D. Nye, et al.. (2018). SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line. Oncotarget. 9(6). 6897–6910. 27 indexed citations

11.

Devi, Gayathri R. & Sritama Nath. (2016). Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. Methods in molecular biology. 1428. 231–243. 1 indexed citations

12.

Evans, Myron K., Scott J. Sauer, Sritama Nath, et al.. (2016). X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death and Disease. 7(1). e2073–e2073. 42 indexed citations

13.

Nath, Sritama & Gayathri R. Devi. (2016). Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. Pharmacology & Therapeutics. 163. 94–108. 688 indexed citations breakdown →

14.

Nath, Sritama, et al.. (2015). Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer. Pancreas. 44(6). 909–917. 33 indexed citations

15.

Kidiyoor, Amritha, Jorge Schettini, Dahlia M. Besmer, et al.. (2014). Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. Frontiers in Immunology. 5. 67–67. 12 indexed citations

16.

Nath, Sritama & Pinku Mukherjee. (2014). MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine. 20(6). 332–342. 652 indexed citations breakdown →

17.

Nath, Sritama, K. Daneshvar, Lopamudra Das Roy, et al.. (2013). MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2(6). e51–e51. 137 indexed citations

18.

Sahraei, Mahnaz, Lopamudra Das Roy, Joseph Curry, et al.. (2012). MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene. 31(47). 4935–4945. 65 indexed citations

19.

Daneshvar, K., et al.. (2012). MicroRNA miR-308 regulates dMyc through a negative feedback loop in Drosophila. Biology Open. 2(1). 1–9. 14 indexed citations

20.

Roy, Lopamudra Das, Mahnaz Sahraei, Durai B. Subramani, et al.. (2010). MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 30(12). 1449–1459. 228 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact